Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
Why Are Non-Mutated EGFR Genes Called "Wild Type?"
Teaching the Immune System to Attack Lung Cancer Tumors
Advice for Lung Cancer Patients: Know Thy Cancer
Is It Necessary for Early Stage Lung Cancer Patients to Get Molecular Testing for Their Tumors?
Treating EGFR Patients After Tarceva Stops Working
Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive Non-small Cell Lung Cancer?
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?
Targeted Treatment for Lung Cancer After Progression
Can Vaccines Fight Lung Cancer?
CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients
Why Do We Call Them "Small Cell Lung Cancer" and "Non-Small Cell Lung Cancer"?
Targeting the RAF Pathway in Lung Cancer
Is It Possible to Test Lung Tumors Without Doing a Biopsy?
What Are PARP Inhibitors, and Might They Improve Outcomes in Small Cell Lung Cancer?
New Insights into Small Cell Lung Cancer
In What Clinical Setting Should Immunotherapies Be Developed?
Maintenance Therapy in Small Cell Lung Cancer
LDE225 and Small Cell Lung Cancer
Is There a Silver Bullet for Small Cell Lung Cancer?
Create your
podcast in
minutes
It is Free
Good Mood Revolution
GRACEcast Pancreatic Cancer Audio
GRACEcast Radiation Oncology Audio
GRACEcast Head and Neck Cancer Video NEW
GRACEcast Kidney Cancer Video
GRACEcast Social Work and Coping Video